Q-omics provides the consensus-scored MARCKSL1 profile across patient tissues and cancer cell-line models. MARCKSL1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MARCKSL1 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, MARCKSL1 protein abundance shows 21,834 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, HNSC, and GBM as cancer lineages where MARCKSL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARCKSL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARCKSL1 survival associations across molecular data types. MARCKSL1 RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARCKSL1 RNA expression–survival associations across cancer types. High MARCKSL1 expression shows unfavorable associations in LIHC, ACC, KICH and SARC, but favorable associations in SCLC and UCEC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MARCKSL1 RNA expression.
This table summarizes MARCKSL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MARCKSL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARCKSL1 shows higher tumor expression in HNSC, COAD, BLCA, KIRC, LUAD and STAD. The HNSC box plot shows higher MARCKSL1 RNA expression in tumor versus normal tissue (log2 FC = +2.051, t-test p < 0.001).
This table shows molecular features associated with MARCKSL1 in patient tissues and cancer cell lines. In patient samples, MARCKSL1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MARCKSL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
